EUR 4.6
(-3.97%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -10.63 Million EUR | 56.36% |
2022 | -24.36 Million EUR | -86.4% |
2021 | -13.06 Million EUR | -1384.53% |
2020 | -880.38 Thousand EUR | -6455.88% |
2019 | -13.42 Thousand EUR | -1533.7% |
2018 | -822.00 EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2023 FY | -10.63 Million EUR | 56.36% |
2023 Q2 | - EUR | 0.0% |
2022 Q2 | -1.28 Million EUR | 0.0% |
2022 Q4 | - EUR | 100.0% |
2022 FY | -24.36 Million EUR | -86.4% |
2021 FY | -13.06 Million EUR | -1384.53% |
2021 Q2 | -438.23 Thousand EUR | 44.03% |
2020 Q2 | -97.45 Thousand EUR | 0.0% |
2020 FY | -880.38 Thousand EUR | -6455.88% |
2020 Q4 | -782.93 Thousand EUR | -703.37% |
2019 FY | -13.42 Thousand EUR | -1533.7% |
2018 FY | -822.00 EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
MPH Health Care AG | 29.54 Million EUR | 135.982% |
Apontis Pharma AG | -11.3 Million EUR | 5.949% |
Dermapharm Holding SE | 62.36 Million EUR | 117.045% |
Evotec SE | -83.91 Million EUR | 87.331% |
MERCK Kommanditgesellschaft auf Aktien | 2.82 Billion EUR | 100.376% |
PharmaSGP Holding SE | 16.39 Million EUR | 164.833% |